effects of the sex, birth cohort, genotype array, and ancestral PCs, the PRS with p < 0.05 accounted for 0.2% of the variance in ever cannabis use (area under the curve (AUC): 0.53 (0.52, 0.54)) and 0.2% of the variance in DSM-5 CUDsx (DSM-5 CUD diagnosis AUC: 0.51 (0.48, 0.55)) (Table 2). No main effects of the PRS were observed for ever use of cannabis or for DSM-5 CUDsx among AA participants (Supplementary Table 2).Table 2Main effects of cannabis initiation polygenic risk scores on cannabis use and DSM-5 cannabis use disorder symptom count in COGA participants of European ancestryThresholdCannabis use ever (lifetime)DSM-5 cannabis use disorder symptom countDSM-5 cannabis use disorder symptom count (among cannabis users) R 2 Betap value R 2 Betap value R 2 Betap valuep < 0.00010.0000.0180.2000.0000.0040.7690.0000.0150.428p < 0.0010.0010.0290.0500.0010.0320.0360.0010.0370.059p < 0.010.0010.0280.0500.0000.0190.2220.0000.0230.249p < 0.05 0.002 0.046 0.001** 0.002 0.041 0.007 0.002 0.039 0.043 p < 0.1 0.001 0.039 0.006 0.002 0.050 0.001** 0.003 0.055 0.005 p < 0.2 0.001 0.039 0.007 0.001 0.040 0.010 0.002 0.041 0.038 p < 0.3 0.001 0.042 0.004 0.001 0.040 0.011 0.002 0.042 0.037 p < 0.4 0.001 0.040 0.006 0.002 0.041 0.009 0.002 0.044 0.029 p < 0.5 0.001 0.038 0.009 0.002 0.041
